Avid Bioservices Inc (CDMO)

[Protector]

nuke661, that is 100% correct.

The discussion was NOT about objective response but about % responses to the drug Opdivo in general. As ex pointed out a number of people benefited from Opdivo by not seeing there tumour progress.

Objective Response < responders in general. In that context PPHM claims that Bavituximab conditioned the tumour environment for Opdivo (and for sure all other anti-XYZ) to have more responders (not just CR, etc but also SD). That includes the Stable Disease.

I do agree with ex that Opdivo is not a BAD drug, certainly not for those people it saves. It's problem is its responders foot-print and the risk one needs to take to find out if one will be a responder or be tackled by the side effects. But with progress it becomes clear that will be found out UPFRONT by looking at the target expression.